home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

69.12 +3.54 (+5.40%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

NetApp, Zoom Video And 2 Other Stocks Insiders Are Selling ↗

April 04, 2024

The Nasdaq 100 closed higher by around 0.2% on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

April 01, 2024

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data

March 25, 2024

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

7 Biotech Stocks to Buy as Sector Rotation Ramps Up ↗

March 13, 2024

With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation.

Via InvestorPlace

Cracking The Code: Understanding Analyst Reviews For Arrowhead Pharma ↗

February 07, 2024

Via Benzinga

Recap: Arrowhead Pharma Q1 Earnings ↗

February 06, 2024

Via Benzinga

Earnings Scheduled For February 6, 2024 ↗

February 06, 2024

Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion.

Via Benzinga

The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024 ↗

March 11, 2024

The Russell 2000 is up about 4% year to date, and could push higher, taking the most undervalued Russell 2000 stocks along for the ride.

Via InvestorPlace

EQT, Genie Energy And Other Big Stocks Moving Lower On Monday ↗

March 11, 2024

U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.

Via Benzinga

Topics Stocks

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

March 08, 2024

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences

March 04, 2024

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

4 Analysts Assess Arrowhead Pharma: What You Need To Know ↗

January 02, 2024

Via Benzinga

Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday ↗

March 01, 2024

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.

Via Benzinga

Topics Stocks

7 Oversold Russell 2000 Stocks to Add to Your February Buy List ↗

February 25, 2024

Investors may want to jump into oversold Russell 2000 stocks. After a rough outing in 2023, many are starting to come back strong.

Via InvestorPlace

Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On. ↗

February 23, 2024

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

Via Investor's Business Daily

7 Biotech Stocks Fighting America’s Deadliest Diseases ↗

February 08, 2024

Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

February 06, 2024

Via Benzinga

Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results

February 06, 2024

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results

January 22, 2024

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million

January 05, 2024

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday ↗

January 04, 2024

U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. (NYSE: LW) rose during Thursday’s session following...

Via Benzinga

Topics Stocks

Why SoFi Technologies Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

January 03, 2024

Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) fell sharply during Wednesday’s session after Keefe, Bruyette & Woods downgraded rating on the stock.

Via Benzinga

Why Arrowhead Pharmaceuticals Shares Are Moving ↗

January 03, 2024

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) shares are trading higher by 5.4% to $32.68, gaining after initially falling, after the company priced an underwritten registered offering of about 15.79...

Via Benzinga

TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday ↗

January 03, 2024

U.S. stocks traded lower, with the Nasdaq Composite falling around 150 points on Wednesday. Shares of TDCX Inc. (NYSE: TDCX) rose sharply during Wednesday’s session after it disclosed receiving a...

Via Benzinga

Topics Stocks

Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock

January 03, 2024

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

December 29, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback ↗

December 29, 2023

Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals.

Via Benzinga

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease

December 21, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 20, 2023

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com